INS and obesity disorder: Identification of more precise genetic subtypes of type 2 diabetes may enable targeted therapies; for example, patients with high genetic risk for beta cell dysfunction may benefit from early initiation of insulin, whereas patients with high genetic risk for obesity-related diabetes may benefit from insulin-sensitising agents.